Treatment of the cutaneous porphyrias

Clinics in Dermatology

Volumn 16, Issue 2, 1998, Pages 295-298

  Mathews Roth, Micheline M ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b CHANNING LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CAROTENE; CHLOROQUINE; LUMITENE; UNCLASSIFIED DRUG;

AVOIDANCE BEHAVIOR; CONGENITAL ERYTHROPOIETIC PORPHYRIA; DIET THERAPY; DRUG EFFICACY; HUMAN; PHLEBOTOMY; PORPHYRIA; PORPHYRIA CUTANEA TARDA; PORPHYRIA VARIEGATA; PRIORITY JOURNAL; REVIEW; VITAMIN INTAKE;

EID: 0032031857     PISSN: 0738081X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0738-081X(97)00208-3     Document Type: Article

References (16)

1. Mathews-Roth MM, Pathak MA, Fitzpatrick TB, et al. Beta-carotene as an oral protective agent in erythropoietic protoporphyria. JAMA 1974;238:1004-8.
2. Mathews-Roth MM, Pathak MA, Fitzpatrick TB, et al. Beta-carotene therapy for erythropoietic protoporphyria and other photosensitivity diseases. Arch Dermatol 1977; 113:1229-32.
3. Mathews-Roth MM. Carotenoids in erythropoietic protoporphyria and other photosensitivity diseases. Ann N Y Acad Sei 1993;691:127-8.
4. Corbett MF, Herxheimer A, Magnus IA, et al. The longterm treatment with beta-carotene in erythropoietic protoporphyria - a controlled trial. Br J Dermatol 1977;97: 655-62.
5. Shaffrir A. Comment to Marsden case report. Proc R Soc Med 1977;70:574.
6. The Alpha-Tocopherol, Beta-carotene Cancer Prevention Study Group. The effect of vitamin E and beta-carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 1994;330:1029-35.
7. Omenn GS, Goodman GE, Thornquist MD, et al. Effects of a combination of beta-carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 1996;334: 1150-5.
8. Hennekens CH, Buring JE, Manson JE, et al. Lack of effect of long-term supplementation with beta-carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med 1996;334:1145-9.
9. Bloomer JR. The liver in protoporphyria. Hepatology 1988;8:402-7.
10. Meerman L, Verwer R, Sloof MJH, et al. Perioperative measures during liver transplantation for erythropoietic protoporphyria. Transplantation 1994;57:155-8.
11. Mathews-Roth MM, Michel JL, Wise RJ. Amelioration of the metabolic defect in erythropoietic protoporphyria by expression of human ferrochelatase in cultured cells. J Invest Dermatol 1995;104:497-9.
12. De Verneuil H, Ged C, Boulechfar S, et al. Porphyrias: Animal models and prospects for cellular and gene therapy. J Bioenerg Biomembr 1995;27:239-48.
13. Magness ST, Brenner DA. Ferrochelatase cDNA delivered by adenoviral vector corrects biochemical defect in protoporphyric cells. Hum Gene Ther 1995;6:1285-90.
14. Guarini L, Piomelli S, Poh-Fitzpatrick M. Hydroxyurea in congenital erythropoietic protoporphyria. N Engl J Med 1994;330:1091-2.
15. Anderson KE, Goeger DE, Carson RW, et al. Erythropoietin for the treatment of porphyria cutanea tarda in a patient on long-term hemodialysis. N Engl J Med 1990;322:315-7.
16. Peces R, Enriquez de Salamanca R, Fontanellas A, et al. Successful treatment of hemodialysis-related porphyria cutanea tarda with erythropoietin. Nephrol Dial Transplant 1994;9:433-5.